摘要
目的比较司库奇尤单抗和阿达木单抗治疗斑块型银屑病(PP)的临床疗效。方法回顾性选取2023年1月至2024年12月开封市人民医院收治的PP患者126例,根据治疗方法将其分为IL-17拮抗剂组(65例)和TNF-α拮抗剂组(61例),IL-17拮抗剂组采用司库奇尤单抗治疗,TNF-α拮抗剂组采用阿达木单抗治疗,IL-17拮抗剂组和TNF-α拮抗剂组患者均持续治疗12周。在治疗12周后,比较两组患者治疗有效率、银屑病面积与严重度指数(PASI)评分、皮肤病生活质量指数(DLQI)评分及不良反应。结果治疗12周后,IL-17拮抗剂组和TNF-α拮抗剂组患者治疗有效率比较,差异无统计学意义(P>0.05)。与治疗前比较,治疗4周后、治疗12周后两组患者PASI、DLQI评分均降低,差异有统计学意义(P<0.05);治疗4周后,IL-17拮抗剂组患者DLQI、PASI评分低于TNF-α拮抗剂组,差异有统计学意义(P<0.05);治疗12周后,两组患者DLQI、PASI评分比较,差异无统计学意义(P>0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论IL-17拮抗剂和TNF-α拮抗剂治疗PP患者均有显著疗效,不良反应发生率无统计学差异,但IL-17拮抗剂能有效改善患者银屑病面积与严重程度,提高患者早期生活质量。
Objective To compare the clinical efficacy of secukinumab and adalimumab in patients with plaque psoriasis(PP).Methods A total of 126 patients with PP who were treated at Kaifeng People’s Hospital from January 2023 to December 2024 were retrospectively enrolled.According to the treatment regimen.they were divided into an IL-17 antagonist group(n=65)and a TNF-αantagonist group(n=61).The IL-17 antagonist group received secukinumab.and the TNF-αantagonist group received adalimumab.Patients in both groups were treated continuously for 12 weeks.After 12 weeks of treatment.the overall response rate.Psoriasis Area and Severity Index(PASI)score.Dermatology Life Quality Index(DLQI)score.and adverse reactions were compared between the two groups.Results After 12 weeks of treatment.there was no statistically significant difference in the overall response rate between the IL-17 antagonist group and the TNF-αantagonist group(P>0.05).Compared with baseline.PASI and DLQI scores decreased in both groups after 4 and 12 weeks of treatment.and the differences were statistically significant(P<0.05).After 4 weeks of treatment.the IL-17 antagonist group had lower DLQI and PASI scores than the TNF-αantagonist group.with statistically significant differences(P<0.05).After 12 weeks of treatment.there were no statistically significant differences in DLQI or PASI scores between the two groups(P>0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Both IL-17 antagonists and TNF-αantagonists show significant efficacy in patients with PP.with no statistically significant difference in the incidence of adverse reactions.However.IL-17 antagonists can more effectively reduce psoriasis area and severity and improve early quality of life in these patients.
作者
靳旺洋
顿耿
张文文
JIN Wangyang;DUN Geng;ZHANG Wenwen(Department of Dermatology,Kaifeng People’s Hospital,Kaifeng Henan 475000,China)
出处
《临床研究》
2026年第2期100-102,共3页
Clinical Research
基金
2023年度开封市科技发展计划项目(2307009)。
